Key Points
- Vincent Vultaggio sold 29,951 shares of Zentalis on Feb. 6 at an average price of $2.43 for $72,780.93, and executed additional early‑February sales — in total selling about 43,320 shares for roughly $105,400.
- Zentalis (NASDAQ:ZNTL) trades near $2.40 (12‑month range $1.01–$3.95) with a market cap around $173M; analysts have a consensus "Hold" rating with a $5.00 target price.
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) insider Vincent Vultaggio sold 6,894 shares of the business's stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $2.42, for a total value of $16,683.48. Following the completion of the sale, the insider owned 146,506 shares of the company's stock, valued at approximately $354,544.52. This represents a 4.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Vincent Vultaggio also recently made the following trade(s):
- On Monday, February 9th, Vincent Vultaggio sold 3,379 shares of Zentalis Pharmaceuticals stock. The stock was sold at an average price of $2.39, for a total transaction of $8,075.81.
- On Friday, February 6th, Vincent Vultaggio sold 29,951 shares of Zentalis Pharmaceuticals stock. The shares were sold at an average price of $2.43, for a total transaction of $72,780.93.
- On Tuesday, February 3rd, Vincent Vultaggio sold 556 shares of Zentalis Pharmaceuticals stock. The shares were sold at an average price of $2.52, for a total transaction of $1,401.12.
- On Monday, February 2nd, Vincent Vultaggio sold 2,540 shares of Zentalis Pharmaceuticals stock. The stock was sold at an average price of $2.55, for a total transaction of $6,477.00.
Zentalis Pharmaceuticals Stock Performance
NASDAQ ZNTL opened at $2.40 on Wednesday. The firm's fifty day moving average is $2.12 and its two-hundred day moving average is $1.73. Zentalis Pharmaceuticals, Inc. has a one year low of $1.01 and a one year high of $3.95. The firm has a market cap of $173.40 million, a PE ratio of -1.16 and a beta of 1.73.
Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.12. Research analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.
Institutional Trading of Zentalis Pharmaceuticals
A number of institutional investors have recently modified their holdings of the business. Millennium Management LLC raised its position in Zentalis Pharmaceuticals by 220.6% in the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company's stock worth $4,881,000 after acquiring an additional 2,111,951 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Zentalis Pharmaceuticals by 0.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company's stock worth $4,386,000 after purchasing an additional 19,768 shares in the last quarter. Acadian Asset Management LLC grew its stake in shares of Zentalis Pharmaceuticals by 4.7% during the 2nd quarter. Acadian Asset Management LLC now owns 2,799,020 shares of the company's stock worth $3,241,000 after purchasing an additional 124,985 shares during the period. Bank of America Corp DE increased its holdings in shares of Zentalis Pharmaceuticals by 117.1% in the 3rd quarter. Bank of America Corp DE now owns 1,548,781 shares of the company's stock valued at $2,339,000 after purchasing an additional 835,466 shares in the last quarter. Finally, Tybourne Capital Management HK Ltd. increased its holdings in shares of Zentalis Pharmaceuticals by 53.7% in the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 1,478,152 shares of the company's stock valued at $1,715,000 after purchasing an additional 516,666 shares in the last quarter.
Analyst Ratings Changes
Several research analysts have weighed in on the company. Leerink Partners reissued a "market perform" rating and issued a $2.00 target price on shares of Zentalis Pharmaceuticals in a report on Tuesday, November 11th. Wall Street Zen raised Zentalis Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Sunday, November 16th. Morgan Stanley dropped their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $4.00 and set an "equal weight" rating on the stock in a research note on Wednesday, November 12th. Finally, Wedbush restated a "neutral" rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $5.00.
Read Our Latest Stock Report on ZNTL
About Zentalis Pharmaceuticals
(
Get Free Report)
Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis' research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.
The company's lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
